

University of Groningen

An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Paraskevas, Kosmas I.; Mikhailidis, Dimitri P.; Ringleb, Peter Arthur; Brown, Martin M.; Dardik, Alan; Poredos, Pavel; Gray, William A.; Nicolaides, Andrew N.; Lal, Brajesh K.; Mansilha, Armando

Published in:
Journal of Vascular Surgery

DOI:
[10.1016/j.jvs.2023.09.031](https://doi.org/10.1016/j.jvs.2023.09.031)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2024

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Paraskevas, K. I., Mikhailidis, D. P., Ringleb, P. A., Brown, M. M., Dardik, A., Poredos, P., Gray, W. A., Nicolaides, A. N., Lal, B. K., Mansilha, A., Antignani, P. L., de Borst, G. J., Cambria, R. P., Loftus, I. M., Lavie, C. J., Blinc, A., Lyden, S. P., Matsumura, J. S., Jezovnik, M. K., ... Goudot, G. (2024). An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis. *Journal of Vascular Surgery*, 79(2), 420-435.e1. <https://doi.org/10.1016/j.jvs.2023.09.031>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Kosmas I. Paraskevas, MD,^a Dimitri P. Mikhailidis, MD, FFPM, FRCP, FRCPath,^b Peter Arthur Ringleb, MD,^c Martin M. Brown, MD,^d Alan Dardik, MD, PhD, FACS, DFSVS, FAHA,^e Pavel Poredos, MD, PhD,^f William A. Gray, MD, FSCAI,^g Andrew N. Nicolaidis, MS, FRCS, PhD (Hons),^{h,i,j} Brajesh K. Lal, MD,^{k,l,m} Armando Mansilha, MD, PhD, FIUA, FEBVS,^{n,o} Pier Luigi Antignani, MD, PhD, FIUA, EFAVF, FESVM, FRSM,^p Gert J. de Borst, MD, PhD, EBSQVasc,^q Richard P. Cambria, MD, FACS,^r Ian M. Loftus, MD, FRCS,^s Carl J. Lavie, MD, FACC,^t Ales Blinc, MD, PhD,^{u,v} Sean P. Lyden, MD, FACS,^w Jon S. Matsumura, MD,^x Mateja K. Jezovnik, MD, PhD,^y J. Michael Bacharach, MD,^z James F. Meschia, MD, FAHA, FAAN, FANA,^{aa} Daniel G. Clair, MD, FACS,^{ab} Clark J. Zeebregts, MD, PhD,^{ac} Gaetano Lanza, MD, PhD,^{ad} Laura Capoccia, MD, PhD,^{ae} Francesco Spinelli, MD, PhD,^{af} Christos D. Liapis, MD, FACS, FRCS, EBSQVasc,^{ag} Arkadiusz Jawien, MD, PhD,^{ah} Sahil A. Parikh, MD, FSCAI,^{ai,aj} Alexei Svetlikov, MD, PhD,^{ak} Gabor Menyhei, MD, PhD, EBSQVasc,^{al} Alun H. Davies, MA, DM, FRCS,^{am} Piotr Musialek, MD, DPhil (Oxford), FESC,^{an} Gary Roubin, MD, PhD,^{ao} Francesco Stilo, MD, PhD,^{af} Sherif Sultan, MD, FRCS, FACS, PhD,^{ap} Robert M. Proczka, MD, PhD,^{aq} Gianluca Faggioli, MD, PhD,^{ar} George Geroulakos, FRCS, DIC, PhD,^{as} Jose Fernandes e Fernandes, MD, PhD, FACS, FRCS Eng, FESC, FEBVS,^{at} Jean-Baptiste Ricco, MD, PhD, FEBVS,^{au} Luca Saba, MD,^{av} Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM,^{aw,ax} Rodolfo Pini, MD, PhD,^{ar} Piotr Myrcha, MD, PhD, MBA,^{ay} Tatjana Rundek, MD, PhD,^{az} Ombretta Martinelli, MD, PhD,^{ba,bb} Stavros K. Kakkos, MD, MSc, PhD, RVT,^{bc} Ravish Sachar, MD, FACC,^{bd} Guillaume Goudot, MD, PhD, FESC,^{be} Felix Schlachetzki, MD,^{bf} George S. Lavenson Jr, MD, FACS, SVS, WVS, SVU, RVT,^{bg} Stefano Ricci, FRCPed,^{bh} Raffi Topakian, MD,^{bi} Antoine Millon, MD, PhD,^{bj} Vincenzo Di Lazzaro, MD,^{bk,bl} Mauro Silvestrini, MD,^{bm} Seemant Chaturvedi, MD,^{bn} Hans-Henning Eckstein, MD, PhD, FEBVS,^{bo} Peter Gloviczki, MD,^{bp} and Christopher J. White, MD, MACC, MSCAI,^{bq,br} Athens, Greece; London, United Kingdom; Heidelberg, Regensburg, and Munich, Germany; New Haven, CT; Ljubljana, Slovenia; Wynnewood, PA; Nicosia, Cyprus; Baltimore, MD; Rochester, MN; Porto, Portugal; Rome, Castellanza, Avezzano, Bologna, Cagliari, Perugia, and Ancona, Italy; Utrecht, and Groningen, The Netherlands; Boston, MA; New Orleans, LA; Cleveland, OH; Madison, WI; Houston, TX; Sioux Falls, SD; Jacksonville, FL; Nashville, TN; Bydgoszcz, Krakow, and Warsaw, Poland; New York, NY; St Petersburg, Russia; Pecs, Hungary; Birmingham, AL; Galway, Ireland; Lisbon, Portugal; Toulouse, Paris, and Bron, France; Miami, FL; Patras, Greece; Raleigh, NC; Bethesda, MD; Wels, Austria; Rochester, MN; and Brisbane, Australia

ABSTRACT

Objective: Despite the publication of various national/international guidelines, several questions concerning the management of patients with asymptomatic (AsxCS) and symptomatic (SxCS) carotid stenosis remain unanswered. The aim of this international, multi-specialty, expert-based Delphi Consensus document was to address these issues to help clinicians make decisions when guidelines are unclear.

Methods: Fourteen controversial topics were identified. A three-round Delphi Consensus process was performed including 61 experts. The aim of Round 1 was to investigate the differing views and opinions regarding these unresolved

From the Department of Vascular Surgery, Central Clinic of Athens, Athens^a; the Division of Surgery and Interventional Science, Department of Surgical Biotechnology, University College London Medical School, University College London (UCL) and Department of Clinical Biochemistry, Royal Free Hospital Campus, UCL, London^b; the Department of Neurology, Heidelberg University Hospital, Heidelberg^c; the Department of Brain Repair and Rehabilitation, Stroke Research Centre, UCL Queen Square Institute of Neurology, University College London, London^d; the Department of Surgery, Yale School of Medicine, New Haven^e; the Department of Vascular Diseases, University Medical

Centre Ljubljana, Ljubljana^f; the Lankenau Heart Institute, Wynnewood^g; the Vascular Screening and Diagnostic Center,^h and the University of Nicosia Medical School,ⁱ Nicosia; the Department of Vascular Surgery, Imperial College, London^j; the Department of Vascular Surgery, University of Maryland School of Medicine,^k and the Department of Vascular Surgery, Baltimore VA Medical Center,^l Baltimore; the Department of Neurology, Mayo Clinic, Rochester^m; the Faculty of Medicine of the University of Porto,ⁿ and the Department of Angiology and Vascular Surgery, Hospital de S. Joao,^o Porto; the Vascular Centre, Nuova Villa Claudia, Rome^p; the Department of Vascular Surgery, University

topics. In Round 2, clarifications were asked from each participant. In Round 3, the questionnaire was resent to all participants for their final vote. Consensus was reached when $\geq 75\%$ of experts agreed on a specific response.

Results: Most experts agreed that: (1) the current periprocedural/in-hospital stroke/death thresholds for performing a carotid intervention should be lowered from 6% to 4% in patients with SxCS and from 3% to 2% in patients with AsxCS; (2) the time threshold for a patient being considered “recently symptomatic” should be reduced from the current definition of “6 months” to 3 months or less; (3) 80% to 99% AsxCS carries a higher risk of stroke compared with 60% to 79% AsxCS; (4) factors beyond the grade of stenosis and symptoms should be added to the indications for revascularization in AsxCS patients (eg, plaque features of vulnerability and silent infarctions on brain computed tomography scans); and (5) shunting should be used selectively, rather than always or never. Consensus could not be reached on the remaining topics due to conflicting, inadequate, or controversial evidence.

Conclusions: The present international, multi-specialty expert-based Delphi Consensus document attempted to provide responses to several unanswered/unresolved issues. However, consensus could not be achieved on some topics, highlighting areas requiring future research. (J Vasc Surg 2024;79:420-35.)

Keywords: Asymptomatic carotid stenosis; Delphi Consensus; Stroke; Symptomatic carotid stenosis; Transient ischemic attack

Medical Center Utrecht, Utrecht^q; the Division of Vascular and Endovascular Surgery, St. Elizabeth's Medical Center, Boston^r; the St George's Vascular Institute, St George's University London, London^s; the John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans^t; the Division of Internal Medicine, Department of Vascular Diseases, University Medical Centre Ljubljana,^u and the Faculty of Medicine, University of Ljubljana,^v Ljubljana; the Department of Vascular Surgery, The Cleveland Clinic, Cleveland^w; the Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison^x; the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Centre at Houston, Houston^y; the Department of Vascular Medicine and Endovascular Intervention, North Central Heart Institute and the Avera Heart Hospital, Sioux Falls^z; the Department of Neurology, Mayo Clinic, Jacksonville^{aa}; the Department of Vascular Surgery, Vanderbilt University Medical Center, Nashville^{ab}; the Department of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen^{ac}; the Vascular Surgery Department, IRCSS Multimedica Hospital, Castellanza^{ad}; the Vascular Surgery Division, Department of Surgery, SS. Filippo e Nicola Hospital, Avezzano^{ae}; the Vascular Surgery Division, Department of Medicine and Surgery, Campus Bio–Medico University of Rome, Rome^{af}; the Athens Vascular Research Center, Athens^{ag}; the Department of Vascular Surgery and Angiology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz^{ah}; the Division of Cardiology, Department of Medicine, New York-Presbyterian Hospital/ Columbia University Irving Medical Center,^{ai} and the Center for Interventional Cardiovascular Care and Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center,^{aj} New York; the Division of Vascular and Endovascular Surgery, North–Western Scientific Clinical Center of Federal Medical Biological Agency of Russia, St Petersburg^{ak}; the Department of Vascular Surgery, University of Pecs, Pecs^{al}; the Department of Surgery and Cancer, Section of Vascular Surgery, Imperial College London, Charing Cross Hospital, London^{am}; the Jagiellonian University Department of Cardiac and Vascular Diseases, John Paul II Hospital, Krakow^{an}; the Department of Cardiology, Cardiovascular Associates of the Southeast/ Brookwood, Baptist Medical Center, Birmingham^{ao}; the Department of Vascular and Endovascular Surgery, Western Vascular Institute, University Hospital Galway, University of Galway, Galway^{ap}; the First Department of Vascular Surgery, Medicover Hospital, Warsaw, Poland, Lazarski University Faculty of Medicine, Warsaw^{aq}; the Vascular Surgery, University of Bologna “Alma Mater Studiorum,” Policlinico S. Orsola Malpighi, Bologna^{ar}; the Department of Vascular Surgery, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens^{as}; the Faculty of Medicine, Lisbon Academic Medical Center, University of

Lisbon, Portugal, Hospital da Luz Torres de Lisboa, Lisbon^{at}; the Department of Vascular Surgery, University Hospital of Toulouse, Toulouse^{au}; the Department of Radiology, Azienda Ospedaliera Universitaria Di Cagliari, Cagliari^{av}; the Division of Cardiology, Department of Medicine, Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center,^{aw} and the Harvard Medical School,^{ax} Boston; the Department of General and Vascular Surgery, Faculty of Medicine, Medical University of Warsaw, Warsaw^{ay}; the Department of Neurology, Miller School of Medicine, University of Miami, Miami^{az}; the Faculty of Medicine, Sapienza University of Rome,^{ba} and the Vascular Surgery Unit, “Umberto I,” Hospital,^{bb} Rome; the Department of Vascular Surgery, University of Patras Medical School, Patras^{bc}; the North Carolina Heart and Vascular Hospital, UNC-REX Healthcare, University of North Carolina, Raleigh^{bd}; the Vascular Medicine Department, Georges Pompidou European Hospital, APHP, Université Paris Cité, Paris^{be}; the Department of Neurology, University Hospital of Regensburg, Regensburg^{bf}; the Department of Surgery, Uniformed Services University, Bethesda^{bg}; the Neurology Department–Stroke Unit, Gubbio-Gualdo Tadino and Citta di Castello Hospitals, USL Umbria 1, Perugia^{bh}; the Department of Neurology, Academic Teaching Hospital Wels-Grieskirchen, Wels^{bi}; the Department of Vascular and Endovascular Surgery, Louis Pradel Hospital, Hospices Civil de Lyon, Bron^{bj}; the Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Università Campus Bio-Medico di Roma,^{bk} and the Fondazione Policlinico Universitario Campus Bio-Medico,^{bl} Roma; the Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Ancona^{bm}; the Department of Neurology, University of Maryland School of Medicine, Baltimore^{bn}; the Department for Vascular and Endovascular Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich^{bo}; the Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester^{bp}; the Department of Medicine and Cardiology, Ochsner Clinical School, University of Queensland, Brisbane^{bq}; and the Department of Cardiology, The John Ochsner Heart and Vascular Institute, New Orleans.^{br}

Additional material for this article may be found online at www.jvascsurg.org.

Correspondence: Kosmas I. Paraskevas, MD, Department of Vascular Surgery, Central Clinic of Athens, 24, Alexander Papagou St, Neo Irakleio, Athens, Greece 14122. (email: paraskevask@hotmail.com).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214

Copyright © 2023 by the Society for Vascular Surgery, Published by Elsevier Inc.

<https://doi.org/10.1016/j.jvs.2023.09.031>

In the past 4 years, several International Societies and Associations (eg, the Society for Vascular Surgery [SVS],^{1,2} the European Society for Vascular Surgery [ESVS],³ the European Stroke Organisation [ESO],⁴ the American Heart Association/American Stroke Association [AHA/ASA],⁵ and others⁶) have released new or have updated their earlier guidelines and recommendations regarding the management of patients with symptomatic (SxCS) and asymptomatic (AsxCS) carotid artery stenosis. Such Society Guidelines¹⁻⁶ are particularly useful because they guide everyday decision-making and clinical practice, thus helping clinicians to optimize the management of their patients.

Despite the release of various guidelines and recommendations,¹⁻⁶ several unanswered and unresolved issues remain. There are a number of reasons to explain the persistence of such unresolved issues, including the paucity of data, the lack of Level I Evidence (ie, randomized controlled trials [RCTs]) to answer a particular question, or the publication of controversial results in the literature. As a result, clinicians and patients may often face situations in which the evidence to support a proposed intervention is sparse or doubtful.⁷ However, even if the evidence is insufficient for evidence-based guidelines, a Delphi-based Trustworthy Consensus Statement can still be carried out.⁷ It is expected that groups of experts can provide recommendations within the context of uncertainty, even if the evidence is considered insufficient.⁸

The aim of the present international, multi-specialty, expert-based Delphi Consensus document was to address the various unresolved issues regarding the management of patients with SxCS and AsxCS to help clinicians in their everyday decision-making. The rationale of gathering experts from different specialties was to avoid “surgical bias” or “interventional cardiologist/radiologist bias.” The aim was to produce a set of objective and balanced recommendations, considering the views and opinions of representative experts from each surgical/interventional and clinical specialty involved in the management of patients with carotid stenosis.

METHODS

An international, multi-specialty, expert-based Delphi Consensus document was prepared in accordance with the Conducting and Reporting Delphi Studies (CREDES) Checklist.⁹ A total of 61 experts from the United States (U.S.) and Europe (Cyprus, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Russia, Slovenia, and the United Kingdom) were invited to participate. Overall, 20 participants were from the U.S. and 41 from Europe. All participants had at least 20 years of relevant clinical experience in the management of patients with carotid artery stenosis and proof of relevant academic expertise, as documented by relevant publications. The experts included were Vascular Surgeons (n = 35),

Neurologists/Stroke Physicians (n = 9), Interventional Cardiologists (n = 8), Vascular Specialists/Angiologists (n = 7), and Interventional Radiologists (n = 2).

Following a search of the literature (PubMed/MedLine, Scopus and EMBASE) and after receiving feedback from the Delphi Consensus participants, a questionnaire was composed consisting of 14 unresolved/unanswered questions (Fig). A total of three rounds were undertaken. When possible, the responses were in a pre-specified seven-answer format (Yes–Probably Yes–Possibly Yes–Uncertain/Unknown/Unproven/No opinion–Possibly No–Probably No–No). The aim of Round 1 was to obtain a broad idea and to investigate the differing views and opinions regarding the various identified unresolved topics. In Round 2, clarifications were requested by the Delphi Consensus coordinator (K.I.P.) on ≥ 1 question from individual participants when the answers provided were not clear enough or did not comply with the pre-specified seven-answer format. All topics were answered in the prespecified seven-answer format except for the routine vs selective vs non-use of shunts (Topic No. 12) and the best material to use for patch closure (Topic No. 13). For each round, all Consensus participants were allowed 2 weeks to provide their responses. Discussion of the results between the Consensus participants and consultation with one another was not permitted. In Round 3, the questionnaire was resent to all participants for their final vote. During this round, all participants additionally received relevant articles from the literature regarding each topic. This frequently led some participants to change their opinion about a topic and to modify their vote. Consensus was reached when $\geq 75\%$ of experts agreed on a preferred response. All information was collected anonymously. No Delphi Consensus participant was identified or was made aware of the identity of the comments by the rest of the participants to avoid any potential bias. Only the Delphi Consensus coordinator was aware of the participant's identity regarding each comment.

The first draft of the Delphi Consensus document was prepared by K.I.P. and was sent to all participants for their feedback. The manuscript was revised twice based on the comments and suggestions of the Delphi participants. All participants approved the final manuscript and provided their consent to proceed with its publication. Any potential conflict of interest of each participant was declared and is listed at the end of this manuscript.

RESULTS

The responses of the 61 Delphi Consensus participants for each pre-identified topic are presented, analyzed, and discussed below. All 61 participants provided answers to all 14 questions. When possible, the responses were in the pre-specified seven-answer format. The response “Uncertain/Unknown/Unproven/No opinion” included one or more of the following.

The 14 questions comprising the Delphi Consensus document.

1. Should the periprocedural/in-hospital stroke/death thresholds for performing CEA/CAS in symptomatic (<6%) and asymptomatic (<3%) patients be reduced to 2% for asymptomatic and 4% for symptomatic patients, as proposed by the 2020 German-Austrian and the 2021 European Stroke Organisation guidelines?
2. Are new ischemic brain lesions after CEA or CAS associated with long-term cognitive impairment?
3. Does severe asymptomatic carotid stenosis cause cognitive impairment and can carotid interventions either reverse or prevent cognitive decline?
4. Is completion duplex ultrasound or angiography useful to lower the risk of postoperative stroke after CEA?
5. Is dual antiplatelet therapy before and during CEA safe and effective in decreasing perioperative thromboembolic complications?
6. Is carotid restenosis after CEA a contra-indication for re-do CEA and (if revascularization is necessary) an indication for CAS?
7. Can TCAR be performed safely in the first 7-14 days after symptom onset with procedural risks similar to CEA?
8. Should the time threshold for a patient being defined as 'recently symptomatic' be reduced from the current definition of '6 months'?
9. Is local/regional anesthesia better than general anesthesia in patients undergoing CEA?
10. Is 80-99% asymptomatic carotid stenosis associated with a higher risk of future ipsilateral ischemic stroke compared with 60-79% stenosis?
11. Should other factors than the grade of stenosis and symptomatology be added to the indications for intervention (e.g., plaque features of vulnerability, presence of intraplaque hemorrhage, etc.)?
12. Should shunting be used routinely, selectively or never?
13. What is the best material to use for patch closure: autologous vein, polyester (Dacron) or biological (Xeno) graft?
14. Should protamine be given to counteract heparin effects at the end of the procedure?

Fig. The 14 questions comprising the Delphi Consensus document. (1) Should the periprocedural/in-hospital stroke/death thresholds for performing carotid endarterectomy (CEA)/carotid artery stenting (CAS) in symptomatic (SxCS) (<6%) and asymptomatic (AsxCS) (<3%) patients be reduced to 2% for patients with SxCS and 4% for patients with AsxCS, as proposed by the 2020 German-Austrian and the 2021 European Stroke Organisation (ESO) guidelines? (2) Are new ischemic brain lesions after CEA or CAS associated with long-term cognitive impairment? (3) Does severe asymptomatic carotid stenosis cause cognitive impairment and can carotid interventions either reverse or prevent cognitive decline? (4) Is completion duplex ultrasound or angiography useful to lower the risk of postoperative stroke after CEA? (5) Is dual antiplatelet therapy (DAPT) before and during CEA safe and effective in decreasing perioperative thromboembolic complications? (6) Is carotid restenosis after CEA a contra-indication for redo CEA and (if revascularization is necessary) an indication for CAS? (7) Can transcrotid artery revascularization (TCAR) be performed safely in the first 7 to 14 days after symptom onset with procedural risks similar to CEA? (8) Should the time threshold for a patient being defined as 'recently symptomatic' be reduced from the current definition of '6 months'? (9) Is local/regional anesthesia better than general anesthesia in patients undergoing CEA? (10) Is 80% to 99% asymptomatic carotid stenosis associated with a higher risk of future ipsilateral ischemic stroke compared with 60% to 79% stenosis? (11) Should other factors than the grade of stenosis and symptomatology be added to the indications for intervention (eg, plaque features of vulnerability, presence of intraplaque hemorrhage, etc)? (12) Should shunting be used routinely, selectively, or never? (13) What is the best material to use for patch closure: autologous vein, polyester (Dacron) or biological (Xeno) graft? (14) Should protamine be given to counteract heparin effects at the end of the procedure?

a. the Consensus participant does not have a (definitive) opinion or does not have enough experience regarding this question (eg, a Neurologist may not know if the best type of patch is Dacron, polytetrafluoroethylene [PTFE], or autologous vein), and/or

b. the evidence supporting a particular question is controversial, conflicting, or inadequate, and/or
c. there is no Level I evidence from RCTs to provide enough evidence, either to support or to refute a particular statement.

Table I. Responses after Rounds 1, 2, and 3 to the question: "Should the periprocedural/in-hospital stroke/death thresholds for performing carotid endarterectomy (CEA)/carotid artery stenting (CAS) in symptomatic (SxCS) (<6%) and asymptomatic (AsxCS) (<3%) patients be reduced to 4% for symptomatic and to 2% for asymptomatic patients, as proposed by the 2020 German-Austrian⁶ and the 2021 European Stroke Organization⁴ (ESO) guidelines?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	57 (93.4)	54 (88.6)
Probably yes	—	3 (4.9)
No	4 (6.6)	3 (4.9)
Probably no	—	1 (1.6)
Total	61 (100)	61 (100)

Should the periprocedural/in-hospital stroke/death thresholds for performing carotid endarterectomy/carotid artery stenting in patients with SxCS (<6%) and AsxCS (<3%) be reduced to 4% for patients with SxCS and to 2% for patients with AsxCS, as proposed by the 2020 German-Austrian⁶ and the 2021 ESO⁴ guidelines?.

Several studies and registries published after 2010 have demonstrated lower perioperative/in-hospital stroke/death rates for patients undergoing carotid endarterectomy (CEA)/CAS compared with earlier studies. For example, a report of CEA (n = 48,185) and CAS (n = 4602) outcomes from nine countries (Australia, Denmark, Finland, Norway, Sweden, Switzerland, Hungary, Italy and the United Kingdom [UK]) demonstrated that the combined stroke and death rate was 0.9% in patients with AsxCS and 2.3% in patients with SxCS.¹⁰ In patients with AsxCS, stroke/death rates were 0.5% in Italy, 0.9% in Australia, 1.6% in Switzerland and 1.8% in the UK.¹⁰ Norway (2.5%) and Sweden (2.7%) reported the highest stroke/death rates, but these were still below the accepted threshold for intervention in patients with AsxCS (<3%).¹⁰ By contrast, for patients with SxCS, all countries reported death/stroke rates <4%, with Italy reporting the lowest (0.9%) and Norway the highest rates (3.8%).¹⁰ Similarly, another registry from the UK presenting the outcomes of 23,235 recent patients with SxCS undergoing CEA, reported a combined 30-day stroke/death rate of 2.31% (95% confidence interval [CI], 2.11-2.50).¹¹

An analysis of all elective CEA (n = 142,074) and CAS procedures (n = 13,086) in Germany between 2009 and 2014 demonstrated that the combined risk of in-hospital periprocedural stroke or death for patients with AsxCS was 1.4% for CEA and 1.7%, for CAS.¹² For patients with SxCS, the in-hospital periprocedural stroke/death risk was 2.5% for CEA and 3.7% for CAS.¹² Based on these results, the 2020 German-Austrian⁶ and subsequently the 2021 ESO⁴ guidelines lowered the

threshold for in-hospital stroke/death rates from 3% to 2% for in-hospital AsxCS and from 6% to 4% for recently symptomatic patients.

Most of the Delphi Consensus document participants (54 of 61; 88.6%) supported that the periprocedural stroke/death thresholds for performing CEA/CAS in both patients with SxCS and AsxCS should be lowered from the values recommended by several current guidelines¹⁻⁶ (Table I). Due to improvements in surgical and endovascular skills/techniques, these lower thresholds (2% for patients with AsxCS and 4% for patients with SxCS) probably represent more reasonable thresholds nowadays.

Are new ischemic brain lesions after CEA or CAS associated with long-term cognitive impairment?.

Several reports have indicated a high incidence of microemboli to the brain after both CEA and CAS.¹³⁻¹⁷ Diffusion-weighted imaging (DWI) has been used to compare the incidence of new ischemic lesions after CEA/CAS. A 2008 systematic review including 32 studies (1363 CAS and 754 CEA procedures) demonstrated that the incidence of any DWI lesion was significantly higher after CAS than after CEA (37% vs 10%, respectively; $P < .01$).¹⁸ A >6-fold higher incidence of DWI lesions with CAS compared with CEA was obtained in a meta-analysis focusing on studies that directly compared the incidence of new DWI lesions after either CEA or CAS (odds ratio [OR], 6.1; 95% CI, 4.19-8.87; $P < .01$).¹⁸ The use of cerebral protection devices reduced the incidence of new ipsilateral DWI lesions after CAS compared with non-use (33% vs 45%, respectively; $P < .01$).¹⁸ The use of closed-cell stents also reduced the incidence of DWI lesions after CAS compared with open-cell designed stents (31% vs 51%, respectively; $P < .01$).¹⁸ Of interest, a significantly higher incidence of new ipsilateral DWI lesions was demonstrated in CEA procedures where shunt use was obligatory compared with selective shunt usage (16% vs 6%, respectively; $P < .01$).¹⁸

Despite the higher number of new ischemic brain lesions after CAS than after CEA, a substudy of the largest RCT comparing CAS with CEA in patients with SxCS, the International Carotid Stenting Study (ICSS), failed to show a difference in cognitive function after the two procedures.¹⁹ Others have supported that ischemic brain lesions seen on DWI after CAS may be a marker of increased risk for recurrent cerebrovascular events.²⁰ It was suggested that patients with periprocedural DWI lesions might benefit from more aggressive and prolonged antiplatelet therapy after CAS.²⁰ Regarding the novel transcrotid artery revascularization (TCAR) procedure, there is some evidence that fewer DWI lesions occur after TCAR compared with transfemoral CAS due to the reversal of blood flow.²¹ It was suggested

Table II. Responses after Rounds 1, 2, and 3 to the question: “Are new ischemic brain lesions after carotid endarterectomy (CEA) or carotid artery stenting (CAS) associated with long-term cognitive impairment?”

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	23 (37.7)	15 (24.6)
Probably yes	11 (18.0)	16 (26.2)
Possibly yes	5 (8.2)	7 (11.5)
Uncertain/unknown/unproven/no opinion	12 (19.7)	15 (24.6)
Probably no	3 (4.9)	–
Possibly no	–	1 (1.6)
No	7 (11.5)	7 (11.5)
Total	61 (100)	61 (100)

that TCAR provides cerebral embolic protection similar to that seen with CEA.²¹

The uncertainty regarding the clinical relevance of silent cerebral emboli after carotid interventions is reflected in the responses of the Delphi Consensus participants (Table II). Nearly one-quarter of the participants (24.6%) supported that there is no solid evidence that ischemic brain lesions after CEA/CAS are associated with long-term cognitive impairment. Notwithstanding a possible effect of new silent cerebral lesions after CEA/CAS/TCAR on cognitive dysfunction, all necessary precautions (eg, filters, cerebral protection devices, and more recently, flow reversal) should be taken to ensure maximum protection from silent ischemic brain lesions after carotid procedures.

Does severe AsxCS cause cognitive impairment and can carotid interventions either reverse or prevent cognitive decline?

The association between AsxCS with cognitive impairment is a highly controversial topic. Several studies have demonstrated a significant association between severe AsxCS and progressive cognitive decline.²²⁻²⁵ A 2021 systematic review including 35 cross-sectional and longitudinal studies demonstrated that >90% of studies (33/35) reported an association between AsxCS and ≥one test showing impaired cognitive function.²⁶ However, it was argued that a ‘significant association’ does not necessarily mean a ‘causal relationship.’²⁶ Several pathophysiological mechanisms were identified by which AsxCS might cause cognitive impairment, including silent cerebral infarction, reduced cerebrovascular reserve, involvement in the pathophysiology of white matter hyperintensities or lacunar infarction, or via a combination of these mechanisms.²⁶

A more recent systematic review including 49 studies similarly demonstrated an association between AsxCS and progressive cognitive deterioration.²⁷ This systematic

review suggested that the most likely mechanisms involved in the cognitive decline observed in patients with AsxCS are probably cerebral hypoperfusion and/or silent cerebral embolization.²⁷ Irrespective of the implicated pathomechanisms, it was concluded that patients with severe AsxCS are at increased risk of developing a progressive decline in several aspects of their cognitive function, including memory, global cognition, and executive function.²⁷

Whether or not carotid interventions can reverse any cognitive decline is another controversial topic. Several studies have demonstrated a beneficial effect of CEA/CAS on cognitive dysfunction, with some neurocognitive domains showing improvement post-procedurally.²⁸⁻³⁰ Other studies, however, have reported mixed results or no significant change after either procedure.³¹⁻³³ A recent systematic review on the topic failed to demonstrate convincing evidence supporting intervention in patients with AsxCS to reverse/prevent cognitive decline.³⁴ According to the 2023 ESVS carotid guidelines,³ carotid interventions are not recommended for the prevention or improvement of cognitive impairment in patients with AsxCS until new research clearly identifies subgroups of patients with AsxCS at risk for developing cognitive impairment, which is then improved by carotid interventions. The controversial results reported in the various studies in the literature and the uncertainty about a possible effect of carotid interventions on cognitive function in patients with AsxCS are also reflected in the heterogeneity of the responses of the Delphi Consensus participants (Table III).

Nearly one-half of the experts (25 of 61; 41%) argued that there is no solid evidence supporting an association between AsxCS and cognitive impairment and/or whether carotid interventions can reverse/prevent cognitive decline. Thus, a consensus could not be reached on this topic.

Is completion duplex ultrasound or angiography useful to lower the risk of postoperative stroke after CEA?

The usefulness of completion duplex ultrasound or angiography in reducing the risk of postoperative stroke after CEA is another controversial issue. A study from Germany including 142,074 elective CEAs from 2009 to 2014 demonstrated an independent association between lower risks of stroke/death with intraoperative completion studies by duplex ultrasound (relative risk [RR], 0.74; 95% CI, 0.63-0.88; *P* = .001) or angiography (RR, 0.80; 95% CI, 0.71-0.90; *P* < .001).³⁵ In contrast, other studies argued against the necessity of routine completion imaging, supporting that it does not improve perioperative outcomes.³⁶⁻³⁸ Consequently, the 2022 SVS carotid guidelines concluded that there is insufficient evidence to recommend routine use of completion imaging after CEA.²

In contrast, a recent systematic review and meta-analysis including 34 studies on intraoperative completion studies

Table III. Responses after Rounds 1, 2, and 3 to the question: "Does severe asymptomatic carotid stenosis (AsxCS) cause cognitive impairment and can carotid interventions either reverse or prevent cognitive decline?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	11 (18.0)	7 (11.5)
Probably yes	22 (36.1)	21 (34.4)
Possibly yes	—	2 (3.3)
Uncertain/unknown/unproven/no opinion	18 (29.5)	25 (41.0)
Probably no	3 (4.9)	3 (4.9)
No	7 (11.5)	3 (4.9)
Total	61 (100)	61 (100)

following CEA using angiography (n = 53,218), intraoperative duplex ultrasound (n = 20,020), flowmetry (n = 16,812), and angiography (n = 2291) reached opposite conclusions.³⁹ This meta-analysis demonstrated that the performance of completion angiography was associated with lower rates of stroke (RR, 0.47; 95% CI, 0.36-0.62; $P < .0001$) and stroke or death (RR, 0.76; 95% CI, 0.70-0.83; $P < .0001$).³⁹ Similarly, the performance of intraoperative completion duplex ultrasound was associated with lower rates of stroke (RR, 0.56; 95% CI, 0.43-0.73; $P < .0001$) and stroke or death (RR, 0.83; 95% CI, 0.74-0.93; $P = .0018$), whereas angiography showed a significant association with lower stroke rates (RR, 0.48; 95% CI, 0.033-0.68; $P = .0001$), but had no effect on the combined stroke or death rate.³⁹ Based largely on these results, the 2023 ESVS carotid guidelines recommended that for patients undergoing CEA, intraoperative completion imaging with angiography, duplex ultrasound, or angiography should be considered to reduce the risk of perioperative stroke (Class IIa; Level of Evidence: B).³

Around 60% of the Delphi Consensus participants supported that completion imaging (mainly in the form of duplex ultrasound) should definitely (29 of 61; 47.4%) or should probably/possibly (8 of 61; 13.2%) be performed to check the results of CEA as this may be useful to reduce the risk of stroke after CEA (Supplementary Table I, online only).

Is dual antiplatelet therapy before and during CEA safe and effective in decreasing perioperative thromboembolic complications? Antiplatelet agents play a key role in the management of patients with AsxCS and SxCS. Although there is no solid evidence to support a benefit of aspirin for AsxCS in terms of reducing stroke rates, the U.S. Preventive Services Task Force recommends initiating low-dose aspirin for primary prevention of cardiovascular disease (CVD) in adults aged 50 to 59 years who have a $\geq 10\%$ 10-year CVD risk, are not at increased

bleeding risk, have a life expectancy of ≥ 10 years and are willing to take low-dose aspirin daily for ≥ 10 years.⁴⁰ In contrast, for adults with a $\geq 10\%$ 10-year CVD risk aged 60 to 69 years, the decision to initiate low-dose aspirin should be individualized, whereas the evidence for adults < 50 or ≥ 70 years is insufficient.⁴⁰

On the other hand, there is considerable evidence to support dual antiplatelet therapy (DAPT) for secondary stroke prevention. In the multicenter (n = 114 centers), randomized, double-blind, placebo-controlled Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular events (CHANCE) trial,⁴¹ 5170 patients were randomized to aspirin plus clopidogrel or aspirin alone within 24 hours of a high-risk transient ischemic attack (TIA) or minor stroke. A stroke occurred in 8.2% of patients in the aspirin + clopidogrel group, compared with 11.7% of patients who took aspirin alone (hazard ratio [HR], 0.68; 95% CI, 0.57-0.81; $P < .001$).⁴¹ Moderate or severe hemorrhage occurred in seven patients (0.3%) in the clopidogrel-aspirin group and eight (0.3%) in the aspirin group ($P = .73$), whereas the rate of hemorrhagic stroke was 0.3% in each group.⁴¹

A meta-analysis including eight RCTs (n = 20,728 patients) comparing aspirin + clopidogrel vs aspirin or clopidogrel alone as secondary prevention of stroke or TIA of arterial origin demonstrated that short-term (≤ 3 months) combination therapy was associated with a 31% reduction in the risk of stroke recurrence (RR, 0.69; 95% CI, 0.59-0.81; $P < .01$), without increasing the risk of hemorrhagic stroke (RR, 1.23; 95% CI, 0.50-3.04; $P = .65$) and major bleeding events (RR, 2.17; 95% CI, 0.18-25.71; $P = .54$).⁴² These RCTs, however, excluded patients that underwent carotid revascularization. Furthermore, short-term combination therapy was associated with a significantly lower risk of major vascular events (RR, 0.70; 95% CI, 0.69-0.82; $P < .01$).⁴² In contrast, long-term (≥ 1 year) treatment with aspirin + clopidogrel did not decrease the risk of stroke recurrence (RR, 0.92; 95% CI, 0.83-1.03, $P = .15$), but was associated with a significantly higher risk of hemorrhagic stroke (RR, 1.67; 95% CI, 1.10-2.56; $P = .02$) and major bleeding events (RR, 1.90; 95% CI, 1.46-2.48; $P < .01$).⁴² Additionally, long-term combination therapy failed to reduce the risk of major vascular events (RR, 0.92; 95% CI, 0.84-1.03; $P = .09$).⁴²

A study including all patients who had undergone transfemoral CAS (n = 18,570) or TCAR (n = 25,459) in the Vascular Quality Initiative database between 2016 and 2021 demonstrated that, compared with DAPT, no antiplatelet therapy (RR, 2.0; 95% CI, 1.2-3.3) or aspirin monotherapy (RR, 2.2; 95% CI, 1.5-3.1) were associated with higher stroke/death rates after transfemoral CAS/TCAR and should be discouraged as unsafe practice.⁴³ On the other hand, P2Y₁₂ inhibitor monotherapy (eg, clopidogrel, ticlopidine, ticagrelor, or prasugrel) was associated with similar rates of stroke/death compared with DAPT with

aspirin plus P2Y12 inhibitor (for TCAR: RR, 0.98; 95% CI, 0.54-1.8; for transfemoral CAS: RR, 0.99; 95% CI, 0.58-1.7).⁴³

Although DAPT seems beneficial over antiplatelet monotherapy for patients undergoing transfemoral CAS or TCAR, this may not apply to patients undergoing CEA. A recent systematic review and meta-analysis of perioperative outcomes of CEA on DAPT vs aspirin monotherapy (n = 11 studies; 47,411 patients; 14,345 on DAPT; 33,066 receiving only aspirin) demonstrated no difference in the rates of perioperative stroke (OR, 0.87; 95% CI, 0.72-1.05) and TIA (OR, 0.78; 95% CI, 0.52-1.17) in the DAPT group compared with the aspirin monotherapy group.⁴⁴ However, DAPT was associated with a nearly 2.8-fold increased risk of neck hematoma (OR, 2.79; 95% CI, 1.87-4.18) and a nearly 2-fold increased risk of reoperation for bleeding (OR, 1.98; 95% CI, 1.77-2.23) compared with aspirin monotherapy.⁴⁴ The authors concluded that "this suggests that the risks of performing CEA on DAPT outweigh the benefits, even in patients with symptomatic carotid stenosis."⁴⁴ These results were verified in other large independent studies.^{45,46} A national registry analysis including >12,000 patients with AsxCS/SxCS undergoing CEA showed that the effectiveness and safety of DAPT did not differ from those of single antiplatelet therapy.⁴⁷ It was concluded that DAPT should be started immediately after a cerebrovascular event and should be continued until 30 days after CEA, followed by single antiplatelet therapy.⁴⁷ Along the same lines, a recent international, multispecialty, expert review and position statement concluded that a short course (<3 months) of DAPT should be initiated within 24 hours of a cerebrovascular event in patients with carotid artery stenosis to reduce the risk of recurrent events.⁴⁸ A similar recommendation was provided in the 2021 AHA/ASA Guidelines.⁵ In patients undergoing TCAR or transfemoral CAS, patients should continue with DAPT for 1 month, after which a P2Y12 inhibitor monotherapy should be continued.⁴⁸

As a result of the conflicting data from the literature, a consensus on this topic could not be reached among the Delphi participants, although two-thirds of the experts thought that DAPT is certainly (33 of 61; 54.1%) or probably/possibly (8 of 61; 13.2%) safe and effective in reducing perioperative thromboembolic events (Supplementary Table II, online only).

Is carotid restenosis after CEA a contraindication for redo CEA and (if revascularization is necessary) an indication for CAS? Due to conflicting data from multicenter RCTs,⁴⁹⁻⁵¹ the optimal management of restenosis after CEA remains a controversial topic. Some RCTs (eg, the Carotid and Vertebral Artery Transluminal Angioplasty Study [CAVATAS]⁴⁹ and the Stent-Protected Angioplasty vs Carotid Endarterectomy [SPACE]⁵⁰ study) reported higher incidence of restenosis after endovascular treatment compared with CEA. However, this did

not translate into a higher incidence of recurrent ipsilateral cerebrovascular events. In contrast, the Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) reported a similar incidence of restenosis after CAS and CEA (6.0 vs 6.3%, respectively; HR, 0.90; 95% CI, 0.63-1.29; $P = .58$).⁵¹

Data from population-based studies demonstrate similar stroke/death rates between redo CEA and CAS after prior ipsilateral CEA.^{52,53} However, re-do CEA carries a higher stroke/death/myocardial infarction (MI) risk for both patients with SxCS and AsxCS compared with patients undergoing primary CEA.⁵² Furthermore, redo CEA may be associated with higher mortality rates compared with CAS, especially in patients with multiple comorbidities.⁵³

A 2017 meta-analysis including prospective data from 11 RCTs demonstrated that the weighted incidence of >70% restenosis was 5.8% after CEA (11 RCTs; 4249 patients) and 10% after CAS (5 RCTs; 2716 patients).⁵⁴ However, CAS patients with untreated >70% restenosis had a mere 0.8% late ipsilateral stroke rate over 50 months of follow-up.⁵⁴ In contrast, over a mean follow-up of 37 months, 13 of 141 CEA patients with >70% restenosis or occlusion suffered a late ipsilateral stroke compared with 33 of 2669 patients who did not have a >70% restenosis or occlusion (9.2% vs 1.2%, respectively; OR, 9.02; 95% CI, 4.70-17.28; $P < .0001$).⁵⁴ Another individual patient-data meta-analysis including 1132 restenosis patients treated in 13 studies (653 patients treated by CAS; 479 patients treated by CEA) demonstrated similar perioperative stroke/death rates with the two procedures (2.3 vs 2.7%, respectively; adjusted OR, 0.8; 95% CI, 0.4-1.8).⁵⁵ However, redo CEA was associated with a 5.5% risk of cranial nerve injury.⁵⁵

Traditionally transfemoral CAS has been used to treat restenosis after CEA. More recently, however, TCAR has been increasingly used to treat restenosis after CEA. A study comparing outcomes after transfemoral CAS vs TCAR for restenosis after prior ipsilateral CEA demonstrated that TCAR was associated with lower 30-day composite outcomes of stroke/death (1.6% vs 2.7%, respectively; $P = .025$), stroke/death/TIA (1.8% vs 3.3%, respectively; $P = .004$), and stroke/death/MI (2.1% vs 3.2%, respectively; $P = .048$) compared with transfemoral CAS.⁵⁶ This difference was primarily driven by lower rates of stroke (1.3% vs 2.3%, respectively; $P = .031$) and TIA (0.2% vs 0.7%, respectively; $P = .031$) for TCAR compared with transfemoral CAS.⁵⁶ A limitation of TCAR is that it is not yet widely available, particularly outside the U.S. However, this situation may change in the future.

The 2023 ESVS Guidelines recommended that for CEA patients with an asymptomatic 70% to 99% restenosis, reintervention may be considered following a multidisciplinary team review (Class IIb; Level of Evidence: A).³ According to the 2022 SVS carotid guidelines,² early recurrent stenosis after CEA can be managed

Table IV. Responses after Rounds 1, 2, and 3 to the question: “Is carotid restenosis after carotid endarterectomy (CEA) a contra-indication for redo CEA and (if revascularization is necessary) an indication for carotid artery stenting (CAS)?”

	Rounds	
	1 & 2, No. (%)	Round 3, No. (%)
Yes	20 (32.8)	16 (26.2)
Probably yes	18 (29.5)	15 (24.6)
Uncertain/unknown/unproven/no opinion	3 (4.9)	1 (1.6)
No	18 (29.5)	21 (34.4)
Probably no	2 (3.3)	8 (13.2)
Total	61 (100)	61 (100)

conservatively unless it is symptomatic, progressive, or causes $\geq 80\%$ luminal stenosis. In contrast, late recurrent stenosis after CEA should be considered for reintervention with similar parameters as primary CEA in both symptomatic and asymptomatic cases.² Reintervention for recurrent stenosis after CEA can involve either redo CEA or CAS, based on the individual patient, clinical scenario, and relevant anatomy.²

The responses of the Delphi Consensus participants are presented in Table IV. Approximately one-half of the participants (29 of 61; 47.6%) did not think that carotid restenosis is an absolute contraindication for redo CEA. However, they advised that in patients with recurrent carotid stenosis, CAS may be preferable due to the increased rates of cranial nerve injury and the presence of neck scarring (“hostile neck”). CAS in these patients appears to be a more attractive option and may thus be preferable in most patients requiring a reintervention.

Can TCAR be performed safely in the first 7 to 14 days after symptom onset with procedural risks similar to CEA? TCAR has quickly gained ground as a hybrid revascularization technique combining the benefits of transfemoral CAS (less invasive nature, avoidance of cranial nerve injury) and at the same time avoiding many of CAS drawbacks (eg, avoidance of aortic arch).⁵⁷⁻⁶³ A recent report showed that TCAR is increasingly performed in the U.S. over the past years and has surpassed transfemoral CAS.⁵⁷ Several reports have demonstrated that TCAR is associated with similar stroke/death rates with CEA in both symptomatic and asymptomatic patients.⁵⁸⁻⁶² However, TCAR has the advantage of avoiding cranial nerve injuries and is associated with a lower risk of postoperative MI compared with CEA.^{60,61} Furthermore, TCAR is associated with lower stroke/death rates compared with transfemoral CAS.⁶³

All current guidelines (ie, the 2021 AHA/ASA,⁵ the 2022 SVS,^{1,2} the 2023 ESVS,³ the 2021 ESO,⁴ and the German-

Austrian⁶ guidelines) provide a strong recommendation for CEA in patients with carotid stenosis within 14 days of a neurologic event (TIA or minor stroke). A recent article used data from the SVS Vascular Quality Initiative database between January 2016 and December 2020 to compare 30-day outcomes of symptomatic patients who had undergone TCAR (n = 1282) or CEA (n = 13,249) within 14 days of a stroke or TIA.⁶⁴ After 1:1 propensity matching, 728 pairs were included for analysis.⁶⁴ The primary composite outcome of stroke, death, or MI was more frequent in patients undergoing TCAR compared with CEA (4.7% vs 2.6%, respectively; $P = .04$). This was driven by a higher rate of postoperative ipsilateral stroke in the TCAR compared with the CEA group (3.8% vs 1.8%, respectively; $P = .005$), whereas no differences were found in terms of death (0.7% vs 0.8%, respectively; $P = .8$) or MI (0.8% vs 1%, respectively; $P = .7$). Furthermore, performing TCAR within 48 hours of a stroke episode was an independent predictor of postoperative stroke or TIA (OR, 5.4; 95% CI, 1.8-16). However, this increased risk of postoperative stroke or TIA was not found when performing TCAR within 48 hours of a TIA episode.⁶⁴ Verification of these preliminary results in larger studies is necessary before any definite conclusions can be drawn.

The responses of the 61 experts regarding the suitability of TCAR to be performed within 7 to 14 days of a recent cerebrovascular event are shown in Table V. Approximately one-half of the Delphi participants (32 of 61; 52.5%) supported that it is not yet known/certain/proven if TCAR can be safely performed in the first 7 to 14 days after symptom onset with procedural risks similar to CEA. This is an area that requires additional research.

Should the time threshold for a patient being defined as ‘recently symptomatic’ be reduced from the current definition of ‘6 months’? Early RCTs recruiting “recently symptomatic patients,” like the European Carotid Surgery Trial (ECST)⁶⁵ or the North American Symptomatic Carotid Endarterectomy Trial (NASCET),⁶⁶ defined “recently symptomatic” patients as those having suffered an ipsilateral TIA or non-disabling stroke within 180 days before study entry. A pooled data analysis from the ECST and NASCET, however, demonstrated that the benefit from surgery was greatest in men, patients ≥ 75 years and those randomized within 2 weeks after their last ischemic event, and it fell rapidly with increasing delay.⁶⁷ As a result, all current guidelines strongly recommend CEA within 2 weeks of a recent cerebrovascular event (TIA or minor stroke).¹⁻⁶ This suggests that the definition of “recently symptomatic patients” as those having suffered a cerebrovascular event within the last 180 days may be inappropriate.

The responses of the 61 Delphi Consensus participants can be seen in Table VI. Overall, $>80\%$ of the study participants (50 of 61; 82.0%) thought that the time threshold

Table V. Responses after Rounds 1, 2, and 3 to the question: “Can transcarotid artery revascularization (TCAR) procedures be performed safely in the first 7 to 14 days after symptom onset with procedural risks similar to carotid endarterectomy (CEA)?”

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	14 (23.0)	8 (13.2)
Probably yes	2 (3.3)	7 (11.5)
Possibly yes	2 (3.3)	1 (1.6)
Uncertain/unknown/unproven/no opinion	28 (45.8)	32 (52.5)
Possibly no	–	1 (1.6)
Probably no	–	1 (1.6)
No	15 (24.6)	11 (18.0)
Total	61 (100)	61 (100)

for patients to be defined as “recently symptomatic” should be reduced from the current definition of “6 months.” Of those, 31 of 50 participants (62.0%) responded that the ‘recently symptomatic’ period should be reduced to 3 months and another eight of 50 (16.0%) thought that it should be reduced to ‘4 weeks/1 month.’ The remaining 11 of 50 participants (22.0%) did not have a strong opinion about what the time threshold for a patient being defined as “recently symptomatic” should be reduced to.

Is local/regional anesthesia better than general anesthesia in patients undergoing CEA? Some surgeons are more comfortable performing CEA under general anesthesia, whereas others prefer local/regional anesthesia to be able to interact with the patient. The General vs Local Anaesthesia (GALA) trial was a multicenter RCT randomly assigning 3526 patients with SxCS or AsxCS from 95 centers in 24 countries to CEA under general ($n = 1753$) or local ($n = 1773$) anesthesia.⁶⁸ The primary outcome (30-day stroke, MI, or death) occurred in 84 patients (4.8%) assigned to surgery under general anesthesia and 80 patients (4.5%) assigned to surgery under local anesthesia.⁶⁸ A non-significant three events per 1000 patients treated were prevented with local anesthesia (95% CI, –11 to 17; risk ratio, 0.94; 95% CI, 0.70-1.27). Furthermore, the two groups did not differ significantly with respect to the quality of life, length of hospital stay, or the primary outcome in the prespecified subgroups of age, contralateral carotid occlusion, and baseline surgical risk.⁶⁸

A recent systematic review and meta-analysis including 31 studies with 152,376 patients demonstrated that local compared with general anesthesia was associated with a shorter surgical time (weighted mean difference: –9.15 minutes; 95% CI, –15.55 to –2.75; $P = .005$) and a 24% reduction in stroke rates (OR, 0.76;

Table VI. Responses after Rounds 1, 2, and 3 to the question: “Should the time threshold for a patient being defined as ‘recently symptomatic’ be reduced from the current definition of ‘6 months’?”

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	45 (73.8)	50 (82.0)
Uncertain/unknown/unproven/no opinion	1 (1.6)	1 (1.6)
Probably not	1 (1.6)	–
No	14 (23.0)	10 (16.4)
Total	61 (100)	61 (100)

95% CI, 0.62-0.92; $P = .006$), a 41% reduction in cardiac complications (OR, 0.59; 95% CI, 0.47-0.73; $P < .00,001$), and a 28% reduction in in-hospital mortality (OR, 0.72; 95% CI, 0.59-0.90; $P = .003$).⁶⁹ Nevertheless, a Cochrane Database Systematic Review including 16 RCTs (4839 patients) failed to show a difference in 30-day stroke (3.2% vs 3.5%, respectively; OR, 0.91; 95% CI, 0.66-1.26; $P = .58$) or stroke and death rates (3.5% vs 4.1%, respectively; OR, 0.85; 95% CI, 0.62-1.16; $P = .31$) between patients undergoing CEA under local vs general anesthesia.⁷⁰

As the preference of the type of anesthesia used varies with each individual surgeon, a consensus was not possible on this topic (Supplementary Table III, online only).

Is 80% to 99% AsxCS associated with a higher risk of future ipsilateral ischemic stroke compared with 60% to 79% AsxCS? According to the 2023 ESVS carotid guidelines, CEA should be considered for average surgical risk patients with 60% to 99% AsxCS in the presence of ≥ 1 imaging or clinical characteristics that may be associated with an increased risk of late stroke, provided 30-day stroke/death rates are $\leq 3\%$ and the patient has at least a 5-year life expectancy (Class IIa; Level of Evidence: B).³ For such patients with AsxCS, CAS may be an alternative to CEA (Class IIb; Level of Evidence: B). One of the imaging parameters associated with an increased risk of late ipsilateral stroke is stenosis progression.³ In the Asymptomatic Carotid Stenosis and Risk of Stroke (ACRS) study, 1121 patients with 50% to 99% AsxCS were followed-up for a mean of 4 years.⁷¹ Regression occurred in 43 individuals (3.8%), no change in 856 study participants (76.4%), and progression in 222 patients (19.8%). For the entire cohort, the 8-year cumulative ipsilateral cerebral ischemic stroke rate was 0% in patients with regression, 9% if the stenosis was unchanged, and 16% if there was progression (average annual stroke rates of 0%, 1.1%, and 2.0%, respectively; log-rank, $P = .05$; RR in patients with progression, 1.92; 95% CI, 1.14-3.25).⁷¹

A systematic review and meta-analysis of all published studies reporting ipsilateral stroke risk in patients with

Table VII. Responses after Rounds 1, 2, and 3 to the question: “Is 80% to 99% asymptomatic carotid stenosis (AsxCS) associated with a higher risk of future ipsilateral ischemic stroke compared with 60% to 79% AsxCS?”

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	47 (77.1)	47 (77.1)
Probably yes	6 (9.8)	7 (11.4)
Possibly yes	1 (1.6)	2 (3.3)
Uncertain/unknown/unproven/no opinion	2 (3.3)	1 (1.6)
Probably no	2 (3.3)	2 (3.3)
Possibly no	1 (1.6)	—
No	2 (3.3)	2 (3.3)
Total	61 (100)	61 (100)

AsxCS identified 56 studies including 13,717 patients; 23 of them ($n = 8419$ patients) provided data on ipsilateral stroke risk fully stratified by degree of AsxCS.⁷² Stroke risk was linearly associated with the degree of ipsilateral stenosis ($P < .0001$).⁷² Patients with 70% to 99% AsxCS had a >two-fold higher stroke risk compared with those individuals with 50% to 69% AsxCS (386 of 3778 vs 181 of 3806 patients; OR, 2.1; 95% CI, 1.7-2.5; $P < .0001$).⁷² Furthermore, patients with 80% to 99% AsxCS had a 2.5-fold higher stroke risk compared with individuals with 50% to 79% AsxCS (77 of 727 vs 167 of 3272 patients; OR, 2.5; 95% CI, 1.8-3.5; $P < .0001$).⁷² The authors concluded that “contrary to the assumptions of current guidelines and the findings of subgroup analyses of previous randomized controlled trials, the stroke risk reported in cohort studies was highly dependent on the degree of asymptomatic carotid stenosis, suggesting that the benefit of endarterectomy might be underestimated in patients with severe stenosis. Conversely, the 5-year stroke risk was low for patients with moderate stenosis on contemporary medical treatment, calling into question any benefit from revascularization.”⁷²

Most of the Delphi participants voted that 80% to 99% AsxCS is definitely (47/61; 77.1%) or is probably (7/61; 11.4%) associated with a higher stroke risk compared with 60% to 79% AsxCS (Table VII).

Should other factors than the grade of stenosis and symptomatology be added to the indications for intervention (eg, plaque features of vulnerability, presence of intraplaque hemorrhage, etc)? In the last few years, it has become apparent that the degree of carotid stenosis alone is not an adequate marker of increased stroke risk, able to indicate when a prophylactic carotid intervention is required.³ Other clinical and radiologic markers have emerged as more accurate predictors of future stroke risk.^{3,73-77} Examples include impaired cerebrovascular

reserve, microembolic signals detected with transcranial Doppler, carotid plaque echolucency, intraplaque hemorrhage on MRI, large juxtaluminal echolucent (black) areas on computerized ultrasound plaque analysis, silent ipsilateral infarction on brain CT scans, etc.⁷³⁻⁷⁷ The presence of one or more such markers of increased future stroke risk may identify high-risk individuals with AsxCS who will benefit from a prophylactic carotid intervention.^{3,73-77}

The 2023 ESVS Carotid Guidelines recommended that for average surgical risk patients with a 60% to 99% AsxCS, CEA should be considered in the presence of one or more imaging or clinical characteristics that may be associated with an increased risk of late stroke, provided 30-day stroke/death rates are $\geq 3\%$ and patient life expectancy exceeds 5 years (Class IIa, Level of Evidence: B). In these patients, CAS may be an alternative to CEA (Class IIb; Level of Evidence: B).³ Nearly all the participants in this Delphi Consensus (>97%) concurred that other factors than the grade of AsxCS and symptomatology should definitely (56 of 61; 91.9%) or should probably/possibly (4 of 61; 6.6%) be added to the indications for intervention in a patient with AsxCS (Table VIII).

Should shunting be used routinely, selectively, or never? The routine vs selective vs non-use of shunts during CEA has been the subject of debate for >3 decades. In addition to numerous studies addressing this issue, this topic has been the subject of Cochrane Database Systematic Reviews since 2000 and has been updated four times.⁷⁸⁻⁸² The first Cochrane Database Systematic Review in 2000 concluded that the data at the time were too limited to either support or refute the use of routine or selective shunting in CEA.⁷⁸ It was also suggested that large-scale RCTs of routine vs selective shunting were required.⁷⁸ Finally, it was concluded that no method of monitoring in selective shunting has been shown to produce better outcomes. The same conclusions have been reached in all subsequent Cochrane Database Systematic Reviews since then, including the latest one published in 2022.⁷⁹⁻⁸²

Vascular surgeons tend to be routine, selective, or never shunters, based on their training. Although there are several methods to monitor brain perfusion during carotid clamping (eg, electroencephalography, stump pressure, backflow, transcranial Doppler monitoring, transcranial cerebral oximetry, and near-infrared spectroscopy), the only reliable method is the patient's neurological status with CEA under locoregional anesthesia. Both the 2022 SVS² and 2023 ESVS³ Guidelines recommended that for patients undergoing CEA, decisions regarding shunting (routine, selective, never) should be considered at the discretion of the operating surgeon.

Based on their personal preference rather than the presence of objective data, most of the Delphi Consensus

Table VIII. Responses after Rounds 1, 2, and 3 to the question: “Should other factors than the grade of stenosis and symptomatology be added to the indications for intervention (eg, plaque features of vulnerability, presence of intraplaque hemorrhage, etc)?”

	Rounds 1 & 2, Round 3	
	No. (%)	No. (%)
Yes	54 (88.5)	56 (91.9)
Probably yes	2 (3.3)	3 (4.9)
Possibly yes	1 (1.6)	1 (1.6)
Uncertain/unknown/unproven/no opinion	2 (3.3)	–
No	2 (3.3)	1 (1.6)
Total	61 (100)	61 (100)

participants (47 of 61; 77.1%) recommended that a shunt be selectively used (Table IX). Nevertheless, it should be noted that this recommendation does not rely on Level I Evidence, but rather on individual preferences.

What is the best material to use for patch closure: autologous vein, polyester (Dacron), or biological (Xeno) graft? The optimal material to use for patch closure in CEA procedures has been the subject of debate for several decades. To define the best patch material, several studies and RCTs have compared different types of patches, namely autologous vein vs synthetic (PTFE or Dacron) vs biological (eg, bovine pericardium).⁸⁵⁻⁸⁸

A 2021 Cochrane Database Systematic Review included 14 trials involving a total of 2278 CEAs with patch closure operations: seven trials compared autologous vein closure vs PTFE closure, five compared Dacron grafts vs other synthetic materials, and two compared bovine pericardium vs other synthetic materials.⁸⁹ Overall, this systematic review concluded that the number of outcome events is too small to allow any meaningful conclusions. There appears to be little (if any) difference in terms of perioperative or long-term ipsilateral stroke rates between the different patch materials.⁸⁹ There is some evidence that PTFE patches may be superior to Dacron grafts in terms of perioperative stroke/TIA rates and both early and late arterial restenosis and occlusion.⁸⁹ Pseudoaneurysm formation may be more common after the use of a vein patch than after the use of a synthetic patch.⁸⁹ Finally, the bovine pericardial patch may reduce the risk of perioperative fatal stroke, death, and infection compared with other synthetic patches.⁸⁹

Both the 2023 ESVS³ and the 2022 SVS² guidelines recommended that for patients undergoing CEA, the choice of patch closure material should be considered at the discretion of the operating surgeon. This is also reflected in the responses of the Delphi Consensus participants, where each vascular surgeon essentially

provided his/her personal preference(s) (Supplementary Table IV, online only). Those participants who were not vascular surgeons did not participate in this topic.

Should protamine be given to counteract heparin effects at the end of the procedure? A 2016 meta-analysis comparing the outcomes in 3817 patients undergoing CEA who received protamine reversal vs 6070 CEA patients who did not receive protamine demonstrated that protamine reversal significantly reduced wound re-exploration for neck hematomas (OR, 0.42; 95% CI, 0.22-0.8; $P = .008$), with no evidence that it increased perioperative stroke rates (OR, 0.71; 95% CI, 0.49-1.03; $P = .07$).⁹⁰ However, the authors reported that, taking into account the limitations of the analysis, further studies were needed to increase the level of evidence provided by their meta-analysis.⁹⁰

A multicenter ($n = 12$) report evaluated whether protamine use after CEA increased within the Vascular Study Group of New England (VSGNE) in response to studies indicating that protamine reduces bleeding complications associated with CEA without increasing the risk of stroke.⁹¹ From 2003 to 2007, protamine use remained stable at 43%. Protamine usage increased to 52% in 2008 ($P < .01$), coincident with new centers joining the VSGNE, and subsequently increased to 62% in 2010 ($P < .01$), shortly after the presentation of the data showing a benefit of protamine use.⁹¹ Reoperation for bleeding was reduced from 1.44% to 0.6% (RR reduction, 57.2%; $P < .001$) without increasing perioperative stroke/death rates.⁹¹

Both the 2022 SVS² and the 2023 ESVS³ guidelines provided a weak recommendation suggesting that protamine reversal of heparin should be considered (Class IIa; Level of Evidence: B). Most vascular surgeons have a personal preference about routine/selective heparin reversal with protamine vs no reversal. Furthermore, one-third of the participants (20 of 61; 32.8%) did not have relevant expertise or did not think that the evidence is solid for or against the use of protamine. Therefore, a consensus on this topic could not be reached (Table X).

DISCUSSION

The present multi-specialty, expert-based Delphi Consensus document provided answers to certain unresolved questions regarding the management of patients with AsxCS and SxCS. At the same time, it revealed topics where the evidence is currently insufficient for definitive conclusions to be drawn and thus identified areas requiring further research. When comparing the views of participants by different area of expertise (eg, surgeons vs non-surgeons), there was no effect of the specialty of each expert on the outcome of each topic.

Most experts agreed that the traditional periprocedural/in-hospital stroke/death thresholds for performing CEA/CAS in SxCS (<6%) and AsxCS (<3%) are now too high

Table IX. Responses after Rounds 1, 2, and 3 to the question: "Should shunting be used routinely, selectively, or never?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Routinely	5 (8.2)	4 (6.6)
Selectively	49 (80.4)	47 (77.1)
Never	1 (1.6)	1 (1.6)
Uncertain/unknown/unproven/no opinion	6 (9.8)	9 (14.7)
Total	61 (100)	61 (100)

and should be reduced. The 2020 German-Austrian,⁶ followed by the 2021 ESO⁴ Guidelines, proposed new lower perioperative thresholds, namely 4% for patients with SxCS and 2% for patients with AsxCS. It could be argued that it may not always be possible to achieve such low stroke/death rates in all patients. Nevertheless, it is worth pursuing the lowest possible stroke/death rates in patients undergoing CEA/CAS/TCAR.

Whether or not new ischemic cerebral lesions after CEA/CAS/TCAR are associated with long-term cognitive impairment is an area that remains uncertain. Although many experts would agree that such silent lesions may have long-term effects on cognitive function, there is no definitive evidence currently available. The same applies to the possible association between AsxCS with cognitive dysfunction, as well as to the role of carotid interventions in reversing cognitive impairment. These are "gray" areas that need to be addressed in well-designed studies in the future.

Although completion imaging after CEA may be preferred or routinely performed by some surgeons, there is no definitive evidence that it reduces postoperative stroke rates. Therefore, some participants were reluctant to recommend completion imaging routinely and consensus could not be achieved. Uncertainty also exists about the value of DAPT before and during CEA (except for recently symptomatic patients),³ the clinical significance and the optimal management of restenosis following CEA, as well as the superiority of local/regional over general anesthesia in patients undergoing CEA.

TCAR has emerged as a considerably better revascularization option compared with transfemoral CAS and is quickly gaining ground in the management of patients with AsxCS and SxCS. Advantages of this procedure include that it can be performed safely under local anesthesia and no intensive care unit stay,⁹² with stroke/death rates comparable to those of the gold-standard CEA.⁹³ Disadvantages include the limited availability of the procedure outside the U.S. and its relatively high cost,⁹⁴ but hopefully these will improve in the future.

Table X. Responses after Rounds 1, 2, and 3 to the question: "Should protamine be given to counteract heparin effects at the end of the procedure?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	16 (26.2)	12 (19.7)
Uncertain/unknown/unproven/ no opinion	10 (16.4)	20 (32.8)
Not routinely	9 (14.7)	11 (18.0)
No	26 (42.7)	18 (29.5)
Total	61 (100)	61 (100)

Most experts agreed that 80% to 99% AsxCS is associated with a higher risk of future ipsilateral ischemic stroke than 60% to 79% AsxCS, but also that other factors besides the degree of stenosis should be valued when deciding to offer an intervention to a patient with AsxCS. There seems to be a gradual change in the way of perceiving increased stroke risk from the classical stratification based on the degree of luminal stenosis. This is certainly an area that requires further investigation. Nevertheless, regardless of the risk of future stroke, patients with severe AsxCS have very high all-cause and cardiac mortality⁹⁵; therefore, aggressive management of vascular risk factors and implementation of best medical treatment is essential for all patients. Finally, the type of patch material selected and the topic of protamine reversal of the effects of heparin after CEA are issues that are largely based on personal preferences of the individual vascular surgeons.

This study has some limitations. Firstly, the opinion of the study participants does not necessarily reflect the opinion of other experts in the field. Secondly, a different composition in the Delphi Consensus group (eg, more stroke physicians or more interventional cardiologists) could have produced different results. Thirdly, all experts provided their recommendations based on the available evidence and their personal experience. In spite of a careful review of the literature, our Delphi Consensus statement still represents the opinion of the participants, rather than facts established by definitive scientific evidence. Their recommendations may differ in the future if new evidence becomes available.

In conclusion, this international, multi-specialty, expert-based Delphi Consensus document attempted to provide answers to several unresolved questions and issues concerning the optimal management of patients with AsxCS and SxCS. Although a consensus was possible on some of these topics, the Delphi participants disagreed on other topics, based largely on their personal clinical experience and interpretation of the available evidence. However, multidisciplinary agreement was achieved in

five areas, and attention was drawn to nine areas that might be the subject for new well-designed scientific studies. In the context of the uncertainty regarding several unanswered questions and until the publication of more robust evidence, as well as Society Practice guidelines addressing these topics, this Consensus document should be viewed as an opportunity to aid clinicians in their everyday quest for the optimal management of patients with SxCS and AsxCS.

AUTHOR CONTRIBUTIONS

Conception and design: KP

Analysis and interpretation: KP, DM, PR, MB, AD, PP, WG, AN, BL, AM, PLA, GB, RPC, IL, CJL, AB, SL, JSM, MJ, JMB, JFM, DC, CZ, GL, LC, FS, CDL, AJ, SP, AS, GM, AHD, PM, GR, FS, SS, RMP, GF, GG, JFF, JR, LS, ES, RP, PM, TR, OM, SK, RS, GG, FS, GSL, SR, RT, ANM, VD, MS, SC, HE, PG, CW

Data collection: KP

Writing the article: KP

Critical revision of the article: KP, DM, PR, MB, AD, PP, WG, AN, BL, AM, PLA, GB, RPC, IL, CJL, AB, SL, JSM, MJ, JMB, JFM, DC, CZ, GL, LC, FS, CDL, AJ, SP, AS, GM, AHD, PM, GR, FS, SS, RMP, GF, GG, JFF, JR, LS, ES, RP, PM, TR, OM, SK, RS, GG, FS, GSL, SR, RT, ANM, VD, MS, SC, HE, PG, CW

Final approval of the article: KP, DM, PR, MB, AD, PP, WG, AN, BL, AM, PLA, GB, RPC, IL, CJL, AB, SL, JSM, MJ, JMB, JFM, DC, CZ, GL, LC, FS, CDL, AJ, SP, AS, GM, AHD, PM, GR, FS, SS, RMP, GF, GG, JFF, JR, LS, ES, RP, PM, TR, OM, SK, RS, GG, FS, GSL, SR, RT, ANM, VD, MS, SC, HE, PG, CW

Statistical analysis: Not applicable

Obtained funding: Not applicable

Overall responsibility: KP

DISCLOSURES

D.P.M. has given talks, acted as a consultant or attended conferences sponsored by Amgen and Novo Nordisk. J.F.M. receives funding from the United States National Institute of Neurologic Disorders and Stroke for work related to running the CREST-2 clinical trial (U01NS080168) and the CREST-2 Long-term Observational Extension study (U01NS119169). E.A.S. has received research grants from the United States Food and Drug Administration, BD, Boston Scientific, Cook, CSI, Laminar Medical, Medtronic and Philips; has received consulting/speaking fees from Abbott, Bayer, BD, Boston Scientific, Cook, Cordis, CSI, Inari, Infraredx, Medtronic, Philips, Shockwave and VentureMed. H.-H.E. is a local Principal Investigator for the ROADSTER 2 trial and a scientific committee member of SPACE-1, SPACE-2 and ACST-2. T.R. is funded by grants from the National Institutes of Health (R01 MD012467, R01 NS029993, R01NS040807, 1U24NS107267), and the National Center for Advancing Translational Sciences (UL1 TR002736, KL2 TR002737). J.S.M. has received institutional

research grants from Abbott, Cook, Endologix, Gore and Medtronic.

REFERENCES

1. AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. *J Vasc Surg*. 2022;51:4S–22S.
2. AbuRahma AF, Avgerinos ED, Chang RW, et al. The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease. *J Vasc Surg*. 2022;75:26S–98S.
3. Naylor R, Rantner B, Ancetti S, et al. ESVS Guidelines Committee. Editor's choice - European society for vascular surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. *Eur J Vasc Endovasc Surg*. 2023;65:7–111.
4. Bonati LH, Kakkos S, Berkefeld J, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. *Eur Stroke J*. 2021;6:1–XLVII.
5. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart association/American stroke association. *Stroke*. 2021;52:e364–e467.
6. Eckstein HH, Kuhn A, Berkefeld J, Lawall H, Storck M, Sander D. Diagnosis, treatment and follow-up in extracranial carotid stenosis. *Dtsch Arztebl Int*. 2020;117:801–807.
7. Lewis SZ, Diekemper R, Ornelas J, Casey KR. Methodologies for the development of CHEST guidelines and expert panel reports. *Chest*. 2014;146:182–192.
8. Neumann I, Schunemann HJ. Guideline groups should make recommendations even if the evidence is considered insufficient. *Can Med Assoc J*. 2020;192:E23–E24.
9. Guidance on conducting and reporting Delphi studies (CREDES) checklist. Accessed June 1, 2023. https://cdn-links.lww.com/permalink/ta/c/ta_00_00_2022_04_14_costantini_jt-d-22-00126_sdc2.pdf
10. Vikatmaa P, Mitchell D, Jensen LP, et al. Variation in clinical practice in carotid surgery in nine countries 2005-2010. Lessons from VAS-CUNET and recommendations for the future of national clinical audit. *Eur J Vasc Endovasc Surg*. 2012;44:11–17.
11. Loftus IM, Paraskevas KI, Johal A, et al. Editor's choice - delays to surgery and procedural risks following carotid endarterectomy in the UK national vascular registry. *Eur J Vasc Endovasc Surg*. 2016;52:438–443.
12. Eckstein HH, Tsantilas P, Kuhn A, et al. Surgical and endovascular treatment of extracranial carotid stenosis. *Dtsch Arztebl Int*. 2017;114:729–736.
13. Poppert H, Wolf O, Resch T, et al. Differences in number, size, and location of intracranial microembolic lesions after surgical versus endovascular treatment without protection device of carotid artery stenosis. *J Neurol*. 2004;251:1198–1203.
14. Iihara K, Murao K, Sakai N, Yamada N, Nagata I, Miyamoto S. Outcome of carotid endarterectomy and stent insertion based on grading of carotid endarterectomy risk: a 7-year prospective study. *J Neurosurg*. 2004;105:546–554.
15. Lacroix V, Hammer F, Astarci P, et al. Ischemic cerebral lesions after carotid surgery and carotid stenting. *Eur J Vasc Endovasc Surg*. 2007;33:430–435.
16. Kastrup A, Nagele T, Groschel K, et al. Incidence of new brain lesions after carotid stenting with and without cerebral protection. *Stroke*. 2006;37:2312–2316.
17. Rapp JH, Wakil L, Sawhney R, et al. Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure. *J Vasc Surg*. 2007;45:867–872.
18. Schnaudigel S, Groschel K, Pilgram SM, Kastrup A. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. *Stroke*. 2008;39:1911–1919.
19. Altinbas A, van Zandvoort MJ, van den Berg E, et al. Cognition after carotid endarterectomy or stenting: a randomized comparison. *Neurology*. 2011;77:1084–1090.
20. Gensicke H, van der Worp HB, Nederkoorn PJ, et al. ICSS-MRI Substudy Investigators. Ischemic brain lesions after carotid artery stenting increase future cerebrovascular risk. *J Am Coll Cardiol*. 2015;65:521–529.

21. Pinter L, Ribo M, Loh C, et al. Safety and feasibility of a novel transcervical access neuroprotection system for carotid artery stenting in the PROOF Study. *J Vasc Surg.* 2011;54:1317–1323.
22. Lazar RM, Wadley VG, Myers T, et al. Baseline cognitive impairment in patients with asymptomatic carotid stenosis in the CREST-2 trial. *Stroke.* 2021;52:3855–3863.
23. Nickel A, Kessner S, Niebuhr A, et al. Cortical thickness and cognitive performance in asymptomatic unilateral carotid artery stenosis. *BMC Cardiovasc Disord.* 2019;19:154.
24. Xiao F, Wang T, Gao L, et al. Frequency-dependent changes of the resting BOLD signals predicts cognitive deficits in asymptomatic carotid artery stenosis. *Front Neurosci.* 2018;12:416.
25. Gray VL, Goldberg AP, Rogers MW, et al. Asymptomatic carotid stenosis is associated with mobility and cognitive dysfunction and heightens falls in older adults. *J Vasc Surg.* 2020;71:1930–1937.
26. Paraskevas KI, Faggioli G, Ancetti S, Naylor AR. Editor's choice - asymptomatic carotid stenosis and cognitive impairment: a systematic review. *Eur J Vasc Endovasc Surg.* 2021;61:888–899.
27. Paraskevas KI, Mikhailidis DP, Spinelli F, et al. Asymptomatic carotid stenosis and cognitive impairment. *J Cardiovasc Surg.* 2023;64:167–173.
28. Lal BK, Younes M, Cruz G, Kapadia I, Jamil Z, Pappas PJ. Cognitive changes after surgery vs stenting for carotid artery stenosis. *J Vasc Surg.* 2011;54:691–698.
29. Takaiwa A, Kuwayama N, Akioka N, et al. Effect of carotid endarterectomy on cognitive function in patients with asymptomatic carotid artery stenosis. *Acta Neurochir.* 2013;155:627–633.
30. Turowicz A, Czapiga A, Malinowski M, Majcherek J, Litarski A, Janczak D. Carotid revascularization improves cognition in patients with asymptomatic carotid artery stenosis and cognitive decline. Greater improvement in younger patients with more disordered neuropsychological performance. *J Stroke Cerebrovasc Dis.* 2021;30:105608.
31. Tiemann L, Reidt JH, Esposito L, Sander D, Theiss W, Poppert H. Neuropsychological sequelae of carotid angioplasty with stent placement: correlation with ischemic lesions in diffusion weighted imaging. *PLoS One.* 2009;4:e7001.
32. Yoshida K, Ogasawara K, Kobayashi M, et al. Improvement and impairment in cognitive function after carotid endarterectomy: comparison of objective and subjective assessments. *Neurol Med Chir (Tokyo).* 2012;52:154–160.
33. Capoccia L, Speziale F, Gazzetti M, et al. Comparative study on carotid revascularization (endarterectomy vs stenting) using markers of cellular brain injury, neuropsychometric tests, and diffusion-weighted magnetic resonance imaging. *J Vasc Surg.* 2010;51:584–591.
34. Ancetti S, Paraskevas KI, Faggioli G, Naylor AR. Editor's choice - effect of carotid interventions on cognitive function in patients with asymptomatic carotid stenosis: a systematic review. *Eur J Vasc Endovasc Surg.* 2021;62:684–694.
35. Knappich C, Kuehnl A, Tsantilas P, et al. Intraoperative completion studies, local anesthesia, and antiplatelet medication are associated with lower risk in carotid endarterectomy. *Stroke.* 2017;48:955–962.
36. Ricotta JJ, O'Brien-Irr MS. Completion angiography: is it really necessary? *Am J Surg.* 1997;174:181–184.
37. Rockman CB, Halm EA. Intraoperative imaging: does it really improve perioperative outcomes of carotid endarterectomy? *Semin Vasc Surg.* 2007;20:236–243.
38. Wallaert JB, Goodney PP, Vignati JJ, et al. Completion imaging after carotid endarterectomy in the vascular study group of new England. *J Vasc Surg.* 2011;54:376–385.
39. Knappich C, Lang T, Tsantilas P, et al. Intraoperative completion studies in carotid endarterectomy: systematic review and meta-analysis of techniques and outcomes. *Ann Transl Med.* 2021;9:1201.
40. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2016;164:836–845.
41. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med.* 2013;369:11–19.
42. Zhang Q, Wang C, Zheng M, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. *Cerebrovasc Dis.* 2015;39:13–22.
43. Marcaccio CL, Patel PB, Rastogi V, et al. Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting. *J Vasc Surg.* 2023;77:1434–1446.
44. Ku JC, Taslimi S, Zuccato J, et al. Editor's choice - peri-operative outcomes of carotid endarterectomy are not improved on dual antiplatelet therapy vs. Aspirin monotherapy: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg.* 2022;63:546–555.
45. Patel RJ, Marmor R, Dakour H, Elsayed N, Ramachandran M, Malas MB. Dual antiplatelet therapy is associated with increased risk of bleeding and decreased risk of stroke following carotid endarterectomy. *Ann Vasc Surg.* 2023;88:191–198.
46. Jones DW, Goodney PP, Conrad MF, et al. Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy. *J Vasc Surg.* 2016;63:1262–1270.
47. Donners SJA, Mekke JM, van Hattum ES, Toorop RJ, de Borst GJ, Dutch Audit for Carotid Interventions (DACI) Collaborators. Editor's choice - risk of bleeding complications with different peri-operative antithrombotic regimens during carotid endarterectomy: a national registry analysis. *Eur J Vasc Endovasc Surg.* 2022;64:444–451.
48. Paraskevas KI, Glociczki P, Mikhailidis DP, et al. Optimal periprocedural antithrombotic treatment in carotid interventions: an international, multispecialty, expert review and position statement. *Prog Cardiovasc Dis.* 2022;74:28–37.
49. Bonati LH, Ederle J, McCabe DJ, et al, CAVATAS Investigators. Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. *Lancet Neurol.* 2009;8:908–917.
50. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol.* 2008;7:893–902.
51. Lal BK, Beach KW, Roubin GS, et al, CREST Investigators. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. *Lancet Neurol.* 2012;11:755–763.
52. Fokkema M, de Borst GJ, Nolan BW, et al, Vascular Study Group of New England. Carotid stenting versus endarterectomy in patients undergoing reintervention after prior carotid endarterectomy. *J Vasc Surg.* 2014;59:8–15.
53. Arhuidese I, Obeid T, Nejim B, Locham S, Hicks CW, Malas MB. Stenting versus endarterectomy after prior ipsilateral carotid endarterectomy. *J Vasc Surg.* 2017;65:1–11.
54. Kumar R, Batchelder A, Saratzis A, et al. Restenosis after carotid interventions and its relationship with recurrent ipsilateral stroke: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg.* 2017;53:766–775.
55. Fokkema M, Vrijenhoek JE, Den Ruijter HM, et al, TREAT CARE Study Group. Stenting versus endarterectomy for restenosis following prior ipsilateral carotid endarterectomy: an individual patient data meta-analysis. *Ann Surg.* 2015;261:598–604.
56. Chang H, Rockman CB, Veith FJ, et al. Outcomes of transfemoral carotid artery stenting and transcarotid artery revascularization for restenosis after prior ipsilateral carotid endarterectomy. *J Vasc Surg.* 2022;75:561–571.
57. Stonko DP, Goldsborough E 3rd, Kibrik P, Zhang G, Holscher CM, Hicks CW. Use of transcarotid artery revascularization, transfemoral carotid artery stenting, and carotid endarterectomy in the US from 2015 to 2019. *JAMA Netw Open.* 2022;5:e2231944.
58. Malas MB, Elsayed N, Naazie I, Dakour-Aridi H, Yei KS, Schermerhorn ML. Propensity score-matched analysis of 1-year outcomes of transcarotid revascularization with dynamic flow reversal, carotid endarterectomy, and transfemoral carotid artery stenting. *J Vasc Surg.* 2022;75:213–222.
59. Zhang GQ, Bose S, Stonko DP, Abularrage CJ, Zarkowsky DS, Hicks CW. Transcarotid artery revascularization is associated with similar outcomes to carotid endarterectomy regardless of patient risk status. *J Vasc Surg.* 2022;76:474–481.
60. Malas MB, Dakour-Aridi H, Kashyap VS, et al. TransCarotid revascularization with dynamic flow reversal versus carotid endarterectomy in the vascular quality initiative surveillance project. *Ann Surg.* 2022;276:398–403.
61. Naazie IN, Cui CL, Osaghae I, Murad MH, Schermerhorn M, Malas MB. A systematic review and meta-analysis of transcarotid artery

- revascularization with dynamic flow reversal versus transfemoral carotid artery stenting and carotid endarterectomy. *Ann Vasc Surg.* 2020;69:426–436.
62. Liang P, Cronenwett JL, Secemsky EA, et al. Risk of stroke, death, and myocardial infarction following transcrotid artery revascularization vs carotid endarterectomy in patients with standard surgical risk. *JAMA Neurol.* 2023;80:437–444.
63. Schermerhorn ML, Liang P, Eldrup-Jorgensen J, et al. Association of transcrotid artery revascularization vs transfemoral carotid artery stenting with stroke or death among patients with carotid artery stenosis. *JAMA.* 2019;322:2313–2322.
64. Elmously A, Rich N, Lazar AN, et al. Outcomes of early transcrotid artery revascularization versus carotid endarterectomy after acute neurologic events. *J Vasc Surg.* 2022;76:760–768.
65. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. *Lancet.* 1991;337:1235–1243.
66. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *N Engl J Med.* 1998;339:1415–1425.
67. Rothwell PM, Eliasziw, Gutnikov SA, Warlow CP, Barnett HJ, Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet.* 2004;363:915–924.
68. GALA Trial Collaborative Group, Lewis SC, Warlow CP, Bodenham AR, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. *Lancet.* 2008;372:2132–2142.
69. Harky A, Chan JSK, Kot TKM, et al. General anaesthesia versus local anaesthesia in carotid endarterectomy. A systematic review and meta-analysis. *J Cardiothorac Vasc Anesth.* 2020;34:219–234.
70. Rerkasem A, Orrapin S, Howard DP, Nantakool S, Rerkasem K. Local versus general anaesthesia for carotid endarterectomy. *Cochrane Database Syst Rev.* 2021;10:CD000126.
71. Kakkos SK, Nicolaidis AN, Charalambous I, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. *J Vasc Surg.* 2014;59:956–967.
72. Howard DPJ, Gaziano L, Rothwell PM, Oxford Vascular Study. Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. *Lancet Neurol.* 2021;20:193–202.
73. Gupta A, Baradaran H, Schweitzer AD, et al. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. *Stroke.* 2013;44:3071–3077.
74. King A, Serena J, Bornstein NM, Markus HS, ACES Investigators. Does impaired cerebrovascular reactivity predict stroke risk in asymptomatic carotid emboli study. *Stroke.* 2011;42:1550–1555.
75. Topkian R, King A, Kwon SU, et al. Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. *Neurology.* 2011;77:751–758.
76. Paraskevas KI, Spence JD, Veith FJ, Nicolaidis AN. Identifying which patients with asymptomatic carotid stenosis could benefit from intervention. *Stroke.* 2014;45:3720–3724.
77. Nicolaidis A, Kakkos SK, Kyriacou E, et al. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. *J Vasc Surg.* 2010;52:1486–1496.
78. Counsell C, Salinas R, Naylor R, Warlow C. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). *Cochrane Database Syst Rev.* 2000;2:CD000190.
79. Bond R, Rerkasem K, Counsell C, et al. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). *Cochrane Database Syst Rev.* 2002;2:CD000190.
80. Rerkasem K, Rothwell PM. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). *Cochrane Database Syst Rev.* 2009;7:CD000190.
81. Chongruksut W, Vaniyapong T, Rerkasem K. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). *Cochrane Database Syst Rev.* 2014;2014:CD000190.
82. Chuatrakoon B, Nantakool S, Rerkasem A, Orrapin S, Howard DP, Rerkasem K. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). *Cochrane Database Syst Rev.* 2022;6:CD000190.
83. Grego F, Antonello M, Lepidi S, Bonvini S, Deriu GP. Prospective, randomized study of external jugular vein patch versus polytetrafluoroethylene patch during carotid endarterectomy: perioperative and long-term results. *J Vasc Surg.* 2003;38:1232–1240.
84. Naylor R, Hayes PD, Payne DA, Allroggen H, Steel S, Thompson MM. Randomized trial of vein versus dacron patching during carotid endarterectomy: long-term results. *J Vasc Surg.* 2004;39:985–993.
85. O'Hara PJ, Hertzner NR, Mascha EJ, Krajewski LP, Clair DG, Ouriel K. A prospective, randomized study of saphenous vein patching versus synthetic patching during carotid endarterectomy. *J Vasc Surg.* 2002;35:324–332.
86. AbuRahma AF, Hopkins ES, Robinson PA, Deel JT, Agarwal S. Prospective randomized trial of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: late follow-up. *Ann Surg.* 2003;237:885–892.
87. Hayes PD, Allroggen H, Steel S, et al. Randomized trial of vein versus Dacron patching during carotid endarterectomy: influence of patch type on postoperative embolization. *J Vasc Surg.* 2001;33:994–1000.
88. Leonore FT, Elsa F, David PC, et al. Short- and long-term outcomes following biological pericardium patches versus prosthetic patches for carotid endarterectomy: a retrospective bicentric study. *Ann Vasc Surg.* 2021;72:66–71.
89. Orrapin S, Benyakorn T, Howard DP, Siribumrungwong B, Rerkasem K. Patches of different types for carotid patch angioplasty. *Cochrane Database Syst Rev.* 2021;2:CD000071.
90. Kakisis JD, Antonopoulos CN, Moulakakis KG, Schneider F, Geroulakos G, Ricco JB. Protamine reduces bleeding complications without increasing the risk of stroke after carotid endarterectomy: a meta-analysis. *Eur J Vasc Endovasc Surg.* 2016;52:296–307.
91. Patel RB, Beaulieu P, Homa K, Goodney PP, Stanley AC, Cronenwett JL. Shared quality data are associated with increased protamine use and reduced bleeding complications after carotid endarterectomy in the Vascular Study Group of New England. *J Vasc Surg.* 2013;58:1518–1524.
92. Mehta V, Tharp P, Caruthers C, Dias A, Wooster M. Transcarotid artery revascularization can safely be performed with regional anaesthesia and no intensive care unit stay. *J Vasc Surg.* 2023;77:555–558.
93. AbuRahma AF, Santini A, AbuRahma ZT, et al. Thirty-day perioperative clinical outcomes of transcrotid artery revascularization vs carotid endarterectomy in a single-center experience. *J Am Coll Surg.* 2023;236:668–674.
94. Cui C, Ramakrishnan G, Murphy J, Malas MB. Cost-effectiveness of transcrotid artery revascularization versus carotid endarterectomy. *J Vasc Surg.* 2021;74:1910–1918.
95. Giannopoulos A, Kakkos S, Abbott A, et al. Long-term mortality in patients with asymptomatic carotid stenosis: Implications for statin therapy. *Eur J Vasc Endovasc Surg.* 2015;50:573–582.

Submitted Aug 22, 2023; accepted Sep 25, 2023.

Additional material for this article may be found online at www.jvascsurg.org.

Supplementary Table I (online only). Responses after Rounds 1, 2, and 3 to the question: "Is completion duplex ultrasound or angiography useful to lower the risk of postoperative stroke after carotid endarterectomy (CEA)?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	22 (36.1)	29 (47.4)
Probably yes for duplex ultrasound	9 (14.7)	4 (6.6)
Possibly yes for duplex ultrasound	2 (3.3)	4 (6.6)
Uncertain/unknown/unproven/no opinion	6 (9.8)	5 (8.2)
Probably no	3 (4.9)	4 (6.6)
Possibly no	2 (3.3)	2 (3.3)
No	17 (27.9)	13 (21.3)
Total	61 (100)	61 (100)

Supplementary Table II (online only). Responses after Rounds 1, 2, and 3 to the question: "Is dual antiplatelet therapy (DAPT) before and during carotid endarterectomy (CEA) safe and effective in decreasing perioperative thromboembolic complications?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	36 (59.0)	33 (54.1)
Probably yes	2 (3.3)	5 (8.2)
Possibly yes	—	3 (4.9)
Uncertain/unknown/unproven/no opinion	16 (26.2)	10 (16.4)
Probably no	—	2 (3.3)
Possibly no	—	1 (1.6)
No	7 (11.5)	7 (11.5)
Total	61 (100)	61 (100)

Supplementary Table III (online only). Responses after Rounds 1, 2, and 3 to the question: "Is local/regional anesthesia better than general anesthesia in patients undergoing carotid endarterectomy (CEA)?"

	Rounds 1 & 2, No. (%)	Round 3, No. (%)
Yes	17 (27.9)	17 (27.9)
Probably yes	4 (6.6)	5 (8.2)
Possibly yes	1 (1.6)	2 (3.3)
Uncertain/unknown/unproven/ no opinion	4 (6.6)	5 (8.2)
Under certain circumstances	4 (6.6)	4 (6.6)
No	31 (50.7)	28 (45.8)
Total	61 (100)	61 (100)

Supplementary Table IV (online only). Responses after Rounds 1, 2, and 3 to the question: "What is the best material to use for patch closure: autologous vein, polyester (Dacron) or biological (Xeno) graft?"

	Rounds 1 & 2, No.	Round 3, No.
Bovine pericardium (xenograft)	17	21
Autologous vein	10	10
PTFE	4	3
Dacron	10	8
Uncertain/unknown/unproven/no opinion	26	27

PTFE, polytetrafluoroethylene.
The reason why the numbers do not add up to 61 is because some participants may equally prefer two different types of patches. In addition, the Delphi Consensus participants who were not vascular surgeons did not participate in this topic.